MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.110
+0.260
+9.12%
Pre Market: 3.130 +0.02 +0.64% 06:26 07/07 EDT
OPEN
2.940
PREV CLOSE
2.850
HIGH
3.150
LOW
2.880
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
1.350
MARKET CAP
260.30M
P/E (TTM)
-1.8756
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABEO stock price target is 9.43 with a high estimate of 18.00 and a low estimate of 4.000.

EPS

ABEO News

More
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 21h ago
Here's Why We're Watching Abeona Therapeutics's (NASDAQ:ABEO) Cash Burn Situation
Simply Wall St. · 3d ago
Hedge Funds Still Crazy About Abeona Therapeutics Inc (ABEO)?
Insider Monkey · 06/23 16:59
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
GlobeNewswire · 06/18 12:30
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire · 06/17 12:30
Krystal Biotech Sued Over The Ownership Of Intellectual Property
Seeking Alpha - Article · 06/12 18:45
Edited Transcript of ABEO earnings conference call or presentation 7-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 06/08 14:11
Penny Stocks to Buy Using Technical Analysis for June 2020
These low-priced stocks may prove exempt from a potential downtrend based on their bullish technical signals.
Investopedia · 05/29 16:14

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About ABEO

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
More

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.